Orphan Pathways Leverage regulatory designations such as Orphan Drug status and Fast Track to accelerate approval timelines and secure exclusivity, enabling strategic co-development and licensing talks with big pharma or hospital systems in the US and EU.

Urgent Care Markets NSTI and SA-AKI are high mortality, no current therapy indications that sit in ICU and trauma pathways, creating prime sales opportunities with hospitals, procurement teams, and payer-aligned care programs; engage clinical champions early.

Market Access Orphan designation supports favorable pricing and reimbursement discussions; position Reltecimod as a value driver for reduced organ failure and shorter ICU stays to justify premium pricing and outcomes-based arrangements with payers and health networks.

Investor Partnerships Past investor interest and a history of financing indicate partnership readiness; leverage momentum to pursue licensing or co-promotion deals with larger biopharma partners following phase 3 results.

Differentiation Edge Reltecimod's immunomodulatory mechanism offers potential first-in-class status for NSTI and SA-AKI, supporting engaging KOLs, formulary discussions, and integration with sepsis care protocols.